Vortioxetine

Generic Name: Vortioxetine

Brand Names: Brintellix, Trintellix

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₂N_₂S

CAS Number: 508233-74-7

Unique Ingredient Identifier: 3O2K1S3WQV

Background: Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of se...

Indication: 用于治疗重度抑郁症成人患者。

Associated Conditions: Major Depressive Disorder (MDD)

Associated Therapies: -

Clinical Trials

MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users

Phase 4

Conditions: Depression
Relapse
Cognitive Impairment

Interventions: Drug: Vortioxetine

First Posted Date: 2019-02-05

Last Posted Date: 2019-11-29

Lead Sponsor: Sir Run Run Shaw Hospital

Target Recruit Count: 220

Registration Number: NCT03830827

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine
Drug: Sertraline
Drug: citalopram
Drug: Escitalopram
Drug: Paroxetine
Drug: Fluoxetine
Drug: Fluvoxamine

First Posted Date: 2018-12-19

Last Posted Date: 2023-05-19

Lead Sponsor: Azienda Ospedaliera Universitaria Integrata Verona

Target Recruit Count: 362

Registration Number: NCT03779789

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Mater Domini, Università Magna Grecia, Catanzaro, Italy
🇮🇹
Sapienza Università di Roma, Dipartimento di Neurologia e Psichiatria, Roma, Italy
🇮🇹
Azienda Ospedaliera Universitaria Verona, Verona, Italy

Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression

Phase 2

Conditions: Bipolar Disorder Depression

Interventions: Drug: Placebo
Drug: Vortioxetine

First Posted Date: 2018-07-26

Last Posted Date: 2018-08-10

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 100

Registration Number: NCT03598868

Locations: 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

Phase 4

Withdrawn

Conditions: Major Depressive Disorder
Type2 Diabetes

Interventions: Drug: Vortioxetine

First Posted Date: 2018-07-10

Last Posted Date: 2022-11-29

Lead Sponsor: Todd Doyle

Registration Number: NCT03580967

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Real-life Effectiveness of Vortioxetine in Depression

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2018-06-13

Last Posted Date: 2021-05-27

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 992

Registration Number: NCT03555136

Locations: 🇺🇸
Pharmacology Research Institute (US0045), Newport Beach, California, United States
🇺🇸
Maxblue Institute (US0038), Hialeah, Florida, United States
🇺🇸
Northwest Behavioral Research Center (US0007), Marietta, Georgia, United States

and more 103 locations

Substance Misuse To Psychiatric Disorders for Cannabis

Phase 2

Completed

Conditions: Depression
Anxiety Disorders
Pharmacotherapy
Cannabis Use Disorder
Depressive State
Anxiety State

Interventions: Drug: Vortioxetine
Other: Treatment as Usual

First Posted Date: 2018-04-02

Last Posted Date: 2023-07-05

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 37

Registration Number: NCT03485274

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

Phase 1

Completed

Conditions: Healthy Adult Participants

Interventions: Drug: Vortioxetine

First Posted Date: 2018-02-19

Last Posted Date: 2019-06-27

Lead Sponsor: Takeda

Target Recruit Count: 28

Registration Number: NCT03437564

Locations: 🇯🇵
Nishi Kumamoto Hospital, Kumamoto, Japan

Cognitive Dysfunction in MDD Patients

Phase 4

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine
Drug: Escitalopram

First Posted Date: 2017-06-14

Last Posted Date: 2019-01-10

Lead Sponsor: Oleg Levada

Target Recruit Count: 150

Registration Number: NCT03187093

Locations: 🇺🇦
State Institution "Zaporizhzhia Medical Academy of Postgraduate Education Ministry of Health of Ukraine", Zaporizhzhia, Ukraine

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Vortioxetine

First Posted Date: 2017-04-11

Last Posted Date: 2021-06-24

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 94

Registration Number: NCT03108625

Locations: 🇵🇱
Centrum Badan Klinicznych PI-House Sp. z o.o., Gdańsk, Poland
🇵🇱
Samodzielny Publiczny Zaklad Opieki Zdrowotnej (SPZOZ) - Centrum Neuropsychiatrii "NEUROMED", Wrocław, Poland
🇷🇸
Clinic of Neurology and Psychiatry for Children and Adolescents, Belgrade, Serbia

and more 28 locations

THINC-it Vortioxetine - Sensitivity to Change

Phase 2

Completed

Conditions: Cognitive Change
Major Depressive Disorder

Interventions: Drug: Vortioxetine
Other: THINC-it Tool

First Posted Date: 2017-02-15

Last Posted Date: 2022-01-20

Lead Sponsor: Brain and Cognition Discovery Foundation

Target Recruit Count: 158

Registration Number: NCT03053362

Locations: 🇨🇦
CRTCE/KJK Healthplex, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy